A.I. Spira

10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial

N. Girard, Wei Li, A.I. Spira et al. · Journal of Thoracic Oncology · 2025 · 15 citations · Full text

Medicine, Oncology, Pharmacology +10

6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)

Salman R. Punekar, Dehan Hong, Jia Luo et al. · Journal of Thoracic Oncology · 2025 · 15 citations · Full text

Medicine, Oncology, Pharmacology +12

Comparative trial of Hexabrix (320 mg iodine/ml), iohexol (300 mg iodine/ml) and Iopamiron (300 mg iodine/ml) in cerebral and spinal angiography: a preliminary report

D Doyon, B. Ducot, P. Halimi et al. · British Journal of Radiology · 1987 · 14 citations

Medicine, Neurosurgery, Surgery +14

ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update.

Manish Patel, Yi‐Long Wu, Zhen Wang et al. · Journal of Clinical Oncology · 2025 · 13 citations

Medicine, Oncology, Pharmacology +16

719MO A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer

Eric Lee, Oladapo Yeku, Ira Winer et al. · Annals of Oncology · 2024 · 11 citations · Full text

Medicine, Gynecology, Oncology +11